25 XP   0   0   10

Edgewise Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Edgewise Therapeutics Inc together

PenkeI guess you are interested in Edgewise Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Edgewise Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Edgewise Therapeutics Inc

I send you an email if I find something interesting about Edgewise Therapeutics Inc.

Quick analysis of Edgewise Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Edgewise Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.7%

What is your share worth?

Current worth
$3.42
Expected worth in 1 year
$3.12
How sure are you?
23.1%

+ What do you gain per year?

Total Gains per Share
$-0.30
Return On Investment
-1.7%

For what price can you sell your share?

Current Price per Share
$17.96
Expected price per share
$12.46 - $20.69
How sure are you?
50%

1. Valuation of Edgewise Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$17.96

Intrinsic Value Per Share

$-16.30 - $-19.34

Total Value Per Share

$-12.87 - $-15.92

2. Growth of Edgewise Therapeutics Inc (5 min.)




Is Edgewise Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$318.8m$303.7m$8.6m2.8%

How much money is Edgewise Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$24.2m-$15.9m-$8.3m-34.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Edgewise Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#176 / 1031

Most Revenue
#947 / 1031

Most Profit
#779 / 1031

Most Efficient
#406 / 1031

What can you expect buying and holding a share of Edgewise Therapeutics Inc? (5 min.)

Welcome investor! Edgewise Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Edgewise Therapeutics Inc.

What can you expect buying and holding a share of Edgewise Therapeutics Inc?

First you should know what it really means to hold a share of Edgewise Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Edgewise Therapeutics Inc is $17.96. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Edgewise Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Edgewise Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.42. Based on the TTM, the Book Value Change Per Share is $-0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Edgewise Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.32-1.8%-0.27-1.5%-0.18-1.0%-0.18-1.0%-0.18-1.0%
Usd Book Value Change Per Share0.311.7%-0.07-0.4%0.191.1%0.261.5%0.261.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.311.7%-0.07-0.4%0.191.1%0.261.5%0.261.5%
Usd Price Per Share10.94-7.77-9.11-11.79-11.79-
Price to Earnings Ratio-8.45--7.21--12.69--22.80--22.80-
Price-to-Total Gains Ratio35.86--16.44--41.54--57.86--57.86-
Price to Book Ratio3.19-2.31-2.85-3.68-3.68-
Price-to-Total Gains Ratio35.86--16.44--41.54--57.86--57.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share17.96
Number of shares55
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.070.26
Usd Total Gains Per Share-0.070.26
Gains per Quarter (55 shares)-4.1214.49
Gains per Year (55 shares)-16.4757.95
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-16-2605848
20-33-420116106
30-49-580174164
40-66-740232222
50-82-900290280
60-99-1060348338
70-115-1220406396
80-132-1380464454
90-148-1540522512
100-165-1700579570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%3.010.00.023.1%3.010.00.023.1%3.010.00.023.1%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.012.07.7%1.00.012.07.7%1.00.012.07.7%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%3.010.00.023.1%3.010.00.023.1%3.010.00.023.1%

Fundamentals of Edgewise Therapeutics Inc

About Edgewise Therapeutics Inc

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Fundamental data was last updated by Penke on 2024-03-20 16:37:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Edgewise Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Edgewise Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Edgewise Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Edgewise Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY--262.1%+262.1%
5Y--455.6%+455.6%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Edgewise Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Edgewise Therapeutics Inc to the Biotechnology industry mean.
  • -8.9% Return on Assets means that Edgewise Therapeutics Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Edgewise Therapeutics Inc:

  • The MRQ is -8.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.9%TTM-7.3%-1.5%
TTM-7.3%YOY-5.1%-2.2%
TTM-7.3%5Y-5.3%-2.0%
5Y-5.3%10Y-5.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.9%-12.5%+3.6%
TTM-7.3%-12.2%+4.9%
YOY-5.1%-11.2%+6.1%
5Y-5.3%-13.4%+8.1%
10Y-5.3%-14.7%+9.4%
1.1.3. Return on Equity

Shows how efficient Edgewise Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Edgewise Therapeutics Inc to the Biotechnology industry mean.
  • -9.5% Return on Equity means Edgewise Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Edgewise Therapeutics Inc:

  • The MRQ is -9.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM-7.8%-1.7%
TTM-7.8%YOY-5.3%-2.5%
TTM-7.8%5Y-5.2%-2.6%
5Y-5.2%10Y-5.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.5%-15.8%+6.3%
TTM-7.8%-15.7%+7.9%
YOY-5.3%-13.9%+8.6%
5Y-5.2%-18.3%+13.1%
10Y-5.2%-19.2%+14.0%

1.2. Operating Efficiency of Edgewise Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Edgewise Therapeutics Inc is operating .

  • Measures how much profit Edgewise Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Edgewise Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Edgewise Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY--279.7%+279.7%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Edgewise Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Edgewise Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY-3.615-3.615
5Y-5.560-5.560
10Y-7.396-7.396

1.3. Liquidity of Edgewise Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Edgewise Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.50 means the company has $19.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Edgewise Therapeutics Inc:

  • The MRQ is 19.498. The company is very able to pay all its short-term debts. +2
  • The TTM is 21.385. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.498TTM21.385-1.887
TTM21.385YOY25.922-4.538
TTM21.3855Y29.887-8.502
5Y29.88710Y29.8870.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.4983.986+15.512
TTM21.3854.440+16.945
YOY25.9225.552+20.370
5Y29.8876.158+23.729
10Y29.8876.492+23.395
1.3.2. Quick Ratio

Measures if Edgewise Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Edgewise Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 32.84 means the company can pay off $32.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Edgewise Therapeutics Inc:

  • The MRQ is 32.836. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 38.740. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ32.836TTM38.740-5.904
TTM38.740YOY47.367-8.628
TTM38.7405Y50.800-12.061
5Y50.80010Y50.8000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.8363.638+29.198
TTM38.7404.168+34.572
YOY47.3675.515+41.852
5Y50.8006.012+44.788
10Y50.8006.209+44.591

1.4. Solvency of Edgewise Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Edgewise Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Edgewise Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Edgewise Therapeutics Inc assets are financed with 6.2% credit (debt) and the remaining percentage (100% - 6.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Edgewise Therapeutics Inc:

  • The MRQ is 0.062. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.060. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.062TTM0.060+0.003
TTM0.060YOY0.046+0.013
TTM0.0605Y0.137-0.078
5Y0.13710Y0.1370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0620.335-0.273
TTM0.0600.330-0.270
YOY0.0460.267-0.221
5Y0.1370.367-0.230
10Y0.1370.378-0.241
1.4.2. Debt to Equity Ratio

Measures if Edgewise Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Edgewise Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.7% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Edgewise Therapeutics Inc:

  • The MRQ is 0.067. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.063. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.067TTM0.063+0.003
TTM0.063YOY0.049+0.015
TTM0.0635Y0.043+0.020
5Y0.04310Y0.0430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0670.376-0.309
TTM0.0630.398-0.335
YOY0.0490.334-0.285
5Y0.0430.429-0.386
10Y0.0430.476-0.433

2. Market Valuation of Edgewise Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Edgewise Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Edgewise Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -8.45 means the investor is paying $-8.45 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Edgewise Therapeutics Inc:

  • The EOD is -13.869. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.448. Based on the earnings, the company is expensive. -2
  • The TTM is -7.209. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.869MRQ-8.448-5.421
MRQ-8.448TTM-7.209-1.239
TTM-7.209YOY-12.686+5.477
TTM-7.2095Y-22.800+15.591
5Y-22.80010Y-22.8000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.869-2.643-11.226
MRQ-8.448-2.418-6.030
TTM-7.209-2.742-4.467
YOY-12.686-4.123-8.563
5Y-22.800-6.257-16.543
10Y-22.800-6.478-16.322
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Edgewise Therapeutics Inc:

  • The EOD is -15.489. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.435. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.415. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.489MRQ-9.435-6.054
MRQ-9.435TTM-7.415-2.019
TTM-7.415YOY-14.858+7.443
TTM-7.4155Y-26.535+19.120
5Y-26.53510Y-26.5350.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.489-3.244-12.245
MRQ-9.435-2.939-6.496
TTM-7.415-3.478-3.937
YOY-14.858-5.592-9.266
5Y-26.535-8.473-18.062
10Y-26.535-8.881-17.654
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Edgewise Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.19 means the investor is paying $3.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Edgewise Therapeutics Inc:

  • The EOD is 5.245. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.195. Based on the equity, the company is fair priced.
  • The TTM is 2.309. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.245MRQ3.195+2.050
MRQ3.195TTM2.309+0.886
TTM2.309YOY2.853-0.544
TTM2.3095Y3.679-1.369
5Y3.67910Y3.6790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.2452.124+3.121
MRQ3.1952.041+1.154
TTM2.3092.118+0.191
YOY2.8532.915-0.062
5Y3.6793.682-0.003
10Y3.6794.114-0.435
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Edgewise Therapeutics Inc.

3.1. Institutions holding Edgewise Therapeutics Inc

Institutions are holding 97.898% of the shares of Edgewise Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Orbimed Advisors, LLC15.6453.18271456717600
2023-12-31FMR Inc6.97290.00556492513896661.4004
2023-12-31Viking Global Investors LP6.61490.2468615914600
2023-12-31Novo A/S6.5214.1019607170300
2023-09-30Deerfield Management Co4.22420.4965393313700
2023-12-31EcoR1 Capital, LLC3.75170.9922349319400
2023-12-31BlackRock Inc3.55180.0009330711032126610.7596
2023-12-31Baker Bros Advisors LP3.34310.387531127862063087196.5408
2023-09-30Citadel Advisors Llc2.97220.00342767436924463.4559
2023-12-31Cormorant Asset Management, LLC2.74081.33342551989-394898-13.4005
2023-12-31Deep Track Capital, LP2.72490.9272537176-212824-7.7391
2023-12-31Vanguard Group Inc2.28260.00052125380609592.9528
2023-12-31Goldman Sachs Group Inc1.89430.0017176379281599886.0944
2023-12-31New Leaf Venture Partners, L.L.C.1.668613.6907155366100
2023-12-31HHG PLC1.30490.00791215013942468.4091
2023-12-31Hudson Bay Capital Management LP1.27580.0824118788011878800
2023-12-31Granahan Investment Management Inc..1.15440.3884107490813578114.4582
2023-12-31Logos Global Management LP1.02030.97019500009500000
2023-12-31Geode Capital Management, LLC1.01710.0011947046552786.1987
2023-12-31State Street Corporation0.95880.000589270910444913.2506
Total 71.639326.821166703755+5363334+8.0%

3.2. Funds holding Edgewise Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.30330.0023214457700
2023-12-31Fidelity Small Cap Growth1.44370.2575134426700
2023-12-31Fidelity Series Small Cap Opps1.4330.26761334255-25100-1.8465
2024-02-29iShares Russell 2000 ETF1.10650.0271030280-168-0.0163
2023-12-31American Century Small Cap Growth Inv0.72510.230567513522145548.813
2023-12-31American Century U.S. Small Cap Growth0.72510.230567513522145548.813
2023-12-31Fidelity Stock Selector Small Cap0.72370.272767384500
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.67810.0101631389-8367-1.3078
2024-01-31Fidelity Advisor Biotechnology I0.60820.599856630000
2024-01-31Fidelity Select Health Care0.5370.11665000005000000
2023-12-31Fidelity Small Cap Growth K60.53670.2604499739290006.1605
2024-01-31Fidelity Select Pharmaceuticals Port0.46860.835843630000
2024-01-31Fidelity Select Biotechnology0.46240.166443058521310097.9838
2023-12-31Fidelity Small Cap Index0.46170.018542991351621.2153
2024-02-01iShares Russell 2000 Value ETF0.43410.06564041555120.1268
2024-02-29iShares Biotechnology ETF0.39790.0795370476-1665-0.4474
2024-01-31Heptagon Driehaus US Micro Cap Eq C$ Acc0.3880.8574361254256276244.1235
2024-01-31Strategic Advisers Fidelity US TtlStk0.37320.006434745091002.6895
2024-01-31Candriam Eqs L Biotech C USD Cap0.35330.3571329000210006.8182
2024-01-31Fidelity Advisor Health Care I0.32220.11073000003000000
Total 14.48184.772413484055+1741760+12.9%

3.3. Insider Transactions

Insiders are holding 0.441% of the shares of Edgewise Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-09John R. MooreSELL802920.01
2024-02-08Behrad DerakhshanSELL460020.01
2024-02-07John R. MooreSELL1799320
2024-01-23Peter A ThompsonBUY45454511
2024-01-23R Michael CarruthersSELL9000015.78
2023-12-27John R. MooreSELL849710.5
2023-12-26Alan J RussellSELL1725859.33
2023-12-26Jonathan C FoxBUY108579.3
2023-05-02Behrad DerakhshanSELL17478.9
2023-05-02Joanne M DonovanSELL32548.9
2023-05-02John R MooreSELL18978.9
2023-05-02Kevin KochSELL32038.9
2023-05-02R Michael CarruthersSELL13368.9

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Edgewise Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.305-0.075+125%0.194+57%0.263+16%0.263+16%
Book Value Per Share--3.4243.355+2%3.262+5%2.969+15%2.969+15%
Current Ratio--19.49821.385-9%25.922-25%29.887-35%29.887-35%
Debt To Asset Ratio--0.0620.060+5%0.046+34%0.137-55%0.137-55%
Debt To Equity Ratio--0.0670.063+5%0.049+37%0.043+55%0.043+55%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---0.324-0.269-17%-0.182-44%-0.179-45%-0.179-45%
Free Cash Flow Per Share---0.290-0.262-10%-0.156-46%-0.161-45%-0.161-45%
Free Cash Flow To Equity Per Share--0.279-0.120+143%0.192+46%0.223+25%0.223+25%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---19.340--------
Intrinsic Value_10Y_min---16.299--------
Intrinsic Value_1Y_max---0.864--------
Intrinsic Value_1Y_min---0.848--------
Intrinsic Value_3Y_max---3.414--------
Intrinsic Value_3Y_min---3.242--------
Intrinsic Value_5Y_max---6.951--------
Intrinsic Value_5Y_min---6.381--------
Market Cap1672266376.000+39%1018629964.000723702138.500+41%848237566.000+20%1097559103.385-7%1097559103.385-7%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio5.245+39%3.1952.309+38%2.853+12%3.679-13%3.679-13%
Pe Ratio-13.869-64%-8.448-7.209-15%-12.686+50%-22.800+170%-22.800+170%
Price Per Share17.960+39%10.9407.773+41%9.110+20%11.788-7%11.788-7%
Price To Free Cash Flow Ratio-15.489-64%-9.435-7.415-21%-14.858+57%-26.535+181%-26.535+181%
Price To Total Gains Ratio58.876+39%35.863-16.440+146%-41.543+216%-57.860+261%-57.860+261%
Quick Ratio--32.83638.740-15%47.367-31%50.800-35%50.800-35%
Return On Assets---0.089-0.073-17%-0.051-42%-0.053-40%-0.053-40%
Return On Equity---0.095-0.078-17%-0.053-43%-0.052-45%-0.052-45%
Total Gains Per Share--0.305-0.075+125%0.194+57%0.263+16%0.263+16%
Usd Book Value--318830000.000312388000.000+2%303707750.000+5%276453307.692+15%276453307.692+15%
Usd Book Value Change Per Share--0.305-0.075+125%0.194+57%0.263+16%0.263+16%
Usd Book Value Per Share--3.4243.355+2%3.262+5%2.969+15%2.969+15%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.324-0.269-17%-0.182-44%-0.179-45%-0.179-45%
Usd Free Cash Flow---26991000.000-24423250.000-10%-14545250.000-46%-14975923.077-45%-14975923.077-45%
Usd Free Cash Flow Per Share---0.290-0.262-10%-0.156-46%-0.161-45%-0.161-45%
Usd Free Cash Flow To Equity Per Share--0.279-0.120+143%0.192+46%0.223+25%0.223+25%
Usd Market Cap1672266376.000+39%1018629964.000723702138.500+41%848237566.000+20%1097559103.385-7%1097559103.385-7%
Usd Price Per Share17.960+39%10.9407.773+41%9.110+20%11.788-7%11.788-7%
Usd Profit---30143000.000-24264000.000-20%-15905500.000-47%-16141000.000-46%-16141000.000-46%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.305-0.075+125%0.194+57%0.263+16%0.263+16%
 EOD+6 -2MRQTTM+15 -14YOY+13 -185Y+13 -1810Y+13 -18

4.2. Fundamental Score

Let's check the fundamental score of Edgewise Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.869
Price to Book Ratio (EOD)Between0-15.245
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than132.836
Current Ratio (MRQ)Greater than119.498
Debt to Asset Ratio (MRQ)Less than10.062
Debt to Equity Ratio (MRQ)Less than10.067
Return on Equity (MRQ)Greater than0.15-0.095
Return on Assets (MRQ)Greater than0.05-0.089
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Edgewise Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.274
Ma 20Greater thanMa 5016.875
Ma 50Greater thanMa 10016.971
Ma 100Greater thanMa 20012.399
OpenGreater thanClose17.380
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,3551,104-251-296-547123-42452399



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets340,035
Total Liabilities21,205
Total Stockholder Equity318,830
 As reported
Total Liabilities 21,205
Total Stockholder Equity+ 318,830
Total Assets = 340,035

Assets

Total Assets340,035
Total Current Assets326,997
Long-term Assets13,038
Total Current Assets
Cash And Cash Equivalents 86,097
Short-term Investments 232,296
Other Current Assets 8,604
Total Current Assets  (as reported)326,997
Total Current Assets  (calculated)326,997
+/-0
Long-term Assets
Property Plant Equipment 12,690
Long-term Assets Other 348
Long-term Assets  (as reported)13,038
Long-term Assets  (calculated)13,038
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities16,771
Long-term Liabilities4,434
Total Stockholder Equity318,830
Total Current Liabilities
Short-term Debt 980
Accounts payable 4,025
Other Current Liabilities 11,766
Total Current Liabilities  (as reported)16,771
Total Current Liabilities  (calculated)16,771
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,434
Long-term Liabilities  (as reported)4,434
Long-term Liabilities  (calculated)4,434
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -244,763
Accumulated Other Comprehensive Income 99
Other Stockholders Equity 563,487
Total Stockholder Equity (as reported)318,830
Total Stockholder Equity (calculated)318,830
+/-0
Other
Capital Stock7
Cash and Short Term Investments 318,393
Common Stock Shares Outstanding 64,775
Liabilities and Stockholders Equity 340,035
Net Debt -80,683
Net Invested Capital 318,830
Net Working Capital 310,226
Property Plant and Equipment Gross 15,306
Short Long Term Debt Total 5,414



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
131,136
311,245
303,493
294,448
285,233
272,745
257,399
377,153
367,101
346,400
330,625
311,364
340,035
340,035311,364330,625346,400367,101377,153257,399272,745285,233294,448303,493311,245131,136000
   > Total Current Assets 
0
0
0
129,645
310,545
302,969
293,242
283,773
268,617
253,343
370,139
356,999
327,952
316,997
297,921
326,997
326,997297,921316,997327,952356,999370,139253,343268,617283,773293,242302,969310,545129,645000
       Cash And Cash Equivalents 
0
0
0
104,916
221,036
50,404
10,571
15,566
34,453
18,341
109,747
21,993
48,230
31,807
32,957
86,097
86,09732,95731,80748,23021,993109,74718,34134,45315,56610,57150,404221,036104,916000
       Short-term Investments 
0
0
0
24,178
88,835
248,747
279,913
265,223
231,380
230,054
255,075
329,954
279,722
278,121
256,740
232,296
232,296256,740278,121279,722329,954255,075230,054231,380265,223279,913248,74788,83524,178000
       Net Receivables 
0
0
0
0
201
0
295
548
559
447
264
251
251
419
0
0
0041925125126444755954829502010000
       Other Current Assets 
0
0
0
551
674
3,818
2,758
2,984
2,784
4,948
5,317
5,052
5,411
7,069
8,224
8,604
8,6048,2247,0695,4115,0525,3174,9482,7842,9842,7583,818674551000
   > Long-term Assets 
0
0
0
1,491
700
524
1,206
1,460
4,128
4,056
7,014
10,102
18,448
13,628
13,443
13,038
13,03813,44313,62818,44810,1027,0144,0564,1281,4601,2065247001,491000
       Property Plant Equipment 
0
0
0
516
499
524
911
912
3,569
3,609
6,750
9,851
12,786
13,209
12,976
12,690
12,69012,97613,20912,7869,8516,7503,6093,569912911524499516000
       Other Assets 
0
0
0
0
201
0
295
548
559
9,004
264
251
0
419
0
0
0041902512649,00455954829502010000
> Total Liabilities 
0
0
0
164,556
4,851
6,739
9,049
10,850
12,389
11,044
15,749
20,385
17,560
19,170
20,937
21,205
21,20520,93719,17017,56020,38515,74911,04412,38910,8509,0496,7394,851164,556000
   > Total Current Liabilities 
0
0
0
4,342
4,851
6,739
8,754
10,521
10,004
9,216
13,303
16,585
12,715
14,400
16,338
16,771
16,77116,33814,40012,71516,58513,3039,21610,00410,5218,7546,7394,8514,342000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
104
216
608
797
872
931
980
980931872797608216104000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
7
0
0
0
0
0
0000070000000000
       Accounts payable 
0
0
0
1,580
1,621
2,816
2,292
3,843
5,340
2,828
5,757
6,105
3,875
3,781
5,318
4,025
4,0255,3183,7813,8756,1055,7572,8285,3403,8432,2922,8161,6211,580000
       Other Current Liabilities 
0
0
0
2,762
3,230
3,923
6,462
6,678
4,664
6,284
7,330
9,872
8,043
9,747
10,089
11,766
11,76610,0899,7478,0439,8727,3306,2844,6646,6786,4623,9233,2302,762000
   > Long-term Liabilities 
0
0
0
160,214
0
0
295
329
2,385
1,828
2,446
3,800
4,845
4,770
4,599
4,434
4,4344,5994,7704,8453,8002,4461,8282,38532929500160,214000
       Other Liabilities 
0
0
0
0
0
0
295
329
187
11,044
0
0
0
0
0
0
00000011,044187329295000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
200
300
300
251
0
419
0
0
00419025130030020000000000
> Total Stockholder Equity
0
0
0
-33,420
306,394
296,754
285,399
274,383
260,356
246,355
361,404
346,716
328,840
311,455
290,427
318,830
318,830290,427311,455328,840346,716361,404246,355260,356274,383285,399296,754306,394-33,420000
   Common Stock
0
0
0
0
5
5
5
5
5
5
6
6
6
6
6
7
7666665555550000
   Retained Earnings Total Equity00-188,907-167,438-144,600-125,185-107,687-91,620-76,960-64,264-51,315-40,9620000
   Accumulated Other Comprehensive Income 
0
0
0
0
-54
-33
-24
-514
-1,932
-2,336
-2,179
-1,355
-251
-547
-424
99
99-424-547-251-1,355-2,179-2,336-1,932-514-24-33-540000
   Capital Surplus 
0
0
0
0
347,405
348,097
349,682
351,852
353,903
356,373
488,762
492,665
496,523
500,903
0
0
00500,903496,523492,665488,762356,373353,903351,852349,682348,097347,4050000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
727
36,160
348,092
55,234
351,852
353,903
356,373
488,762
492,665
496,523
500,903
505,465
563,487
563,487505,465500,903496,523492,665488,762356,373353,903351,85255,234348,09236,160727000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,732
Gross Profit-1,732-1,732
 
Operating Income (+$)
Gross Profit-1,732
Operating Expense-112,625
Operating Income-114,357-114,357
 
Operating Expense (+$)
Research Development89,354
Selling General Administrative23,452
Selling And Marketing Expenses181
Operating Expense112,625112,987
 
Net Interest Income (+$)
Interest Income14,194
Interest Expense-0
Other Finance Cost-0
Net Interest Income14,194
 
Pretax Income (+$)
Operating Income-114,357
Net Interest Income14,194
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-100,163-128,551
EBIT - interestExpense = -114,357
-100,163
-100,163
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-114,357-100,163
Earnings Before Interest and Taxes (EBITDA)-112,625
 
After tax Income (+$)
Income Before Tax-100,163
Tax Provision-0
Net Income From Continuing Ops-100,163-100,163
Net Income-100,163
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses114,357
Total Other Income/Expenses Net14,194-14,194
 

Technical Analysis of Edgewise Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Edgewise Therapeutics Inc. The general trend of Edgewise Therapeutics Inc is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Edgewise Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Edgewise Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 18.37 < 20.69.

The bearish price targets are: 15.43 > 14.33 > 12.46.

Tweet this
Edgewise Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Edgewise Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Edgewise Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Edgewise Therapeutics Inc. The current macd is 0.0628322.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Edgewise Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Edgewise Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Edgewise Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Edgewise Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEdgewise Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Edgewise Therapeutics Inc. The current adx is 19.21.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Edgewise Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Edgewise Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Edgewise Therapeutics Inc. The current sar is 15.43.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Edgewise Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Edgewise Therapeutics Inc. The current rsi is 58.27. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Edgewise Therapeutics Inc Daily Relative Strength Index (RSI) ChartEdgewise Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Edgewise Therapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Edgewise Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Edgewise Therapeutics Inc Daily Stochastic Oscillator ChartEdgewise Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Edgewise Therapeutics Inc. The current cci is 134.35.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Edgewise Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEdgewise Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Edgewise Therapeutics Inc. The current cmo is 23.10.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Edgewise Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEdgewise Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Edgewise Therapeutics Inc. The current willr is -13.94557823.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Edgewise Therapeutics Inc Daily Williams %R ChartEdgewise Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Edgewise Therapeutics Inc. The current atr is 1.0313476.

Edgewise Therapeutics Inc Daily Average True Range (ATR) ChartEdgewise Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Edgewise Therapeutics Inc. The current obv is 22,859,162.

Edgewise Therapeutics Inc Daily On-Balance Volume (OBV) ChartEdgewise Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Edgewise Therapeutics Inc. The current mfi is 71.80.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Edgewise Therapeutics Inc Daily Money Flow Index (MFI) ChartEdgewise Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Edgewise Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Edgewise Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Edgewise Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.274
Ma 20Greater thanMa 5016.875
Ma 50Greater thanMa 10016.971
Ma 100Greater thanMa 20012.399
OpenGreater thanClose17.380
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Edgewise Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Edgewise Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Edgewise Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Edgewise Therapeutics Inc

I send you an email if I find something interesting about Edgewise Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Edgewise Therapeutics Inc.

Receive notifications about Edgewise Therapeutics Inc in your mailbox!